Research has shown that variations in the OCT1 gene play a significant role in the varying effectiveness of metformin treatment for individuals with T2DM (Gambineri et al., 2010; Umamaheswaran et al., 2015; Sundelin et al., 2017; Chan et al., 2018). Here, SLC22A1 is linked to type 2 diabetes mellitus.